Related Experiment Video
Updated: Aug 14, 2026
Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
MDM2 in Breast Cancer
1Department of Surgery. Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyou-ku, Tokyo 113, Japan.
Abstract:
The MDM2 protein, an oncogene product, is known to act by suppressing p53 function. Although gene amplification of MDM2 was frequently detected in human sarcomas, it was uncommon in the majority of epithelial tumors including breast cancer. However, recent reports have demonstrated that its translational activity is enhanced in a variety of carcinomas. In this report, we summarized the implications of MDM2 overexpression in human breast cancer from the literature as well as our preliminary results.
Insights
MDM2 protein overexpression, while not common via gene amplification in breast cancer, shows enhanced translational activity. This suggests MDM2
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MDM2 protein, an oncogene product, regulates tumor suppressor p53.
- MDM2 gene amplification is frequent in sarcomas but rare in epithelial tumors like breast cancer.
- Recent studies indicate increased MDM2 translational activity in various carcinomas.
Purpose of the Study:
- To review the literature on MDM2 overexpression in human breast cancer.
- To present preliminary findings on the role of MDM2 in breast cancer.
Main Methods:
- Literature review of MDM2's role in breast cancer.
- Analysis of preliminary experimental results (details not specified in abstract).
Main Results:
- MDM2 overexpression is implicated in human breast cancer.
- Enhanced translational activity of MDM2 is observed in carcinomas.
Conclusions:
- MDM2's role in breast cancer warrants further investigation, particularly regarding its translational regulation.
- Understanding MDM2 overexpression mechanisms is crucial for breast cancer research.
